Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF +0.72% Cash-to-Debt is 0.13 as of Jun. 2026, which is 96% below its 10-year median of 3.14. The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks worse than 88.95% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. VentriPoint Diagnostics's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.13.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, VentriPoint Diagnosticscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for VentriPoint Diagnostics's Cash-to-Debt or its related term are showing as below:
VPTDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 3.14 Max: No Debt
Current: 0.13
During the past 13 years, VentriPoint Diagnostics's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 3.14.
VPTDF's Cash-to-Debt is ranked worse than 88.95% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs VPTDF: 0.13
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
VentriPoint Diagnostics Cash-to-Debt Related Terms
VentriPoint Diagnostics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, VentriPoint Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a Cash-to-Debt of 0.13 as of Jun. 2026. This is 96% below median its historical median of 3.14. Over the past decade, VentriPoint Diagnostics' Cash-to-Debt has ranged from 0.01 to 10,000.00. According to the industry distribution chart, VentriPoint Diagnostics ranks #749 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 89%.
Is VentriPoint Diagnostics' Cash-to-Debt too high?
VentriPoint Diagnostics' current Cash-to-Debt of 0.13 is 96% below median its 10-year median of 3.14. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.61. VentriPoint Diagnostics' value of 0.13 is 91.9% below this industry median. Based on the distribution chart, VentriPoint Diagnostics ranks #749 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does VentriPoint Diagnostics' Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #749 out of 842 companies for Cash-to-Debt. This places VentriPoint Diagnostics in the lower half of its industry. The industry median Cash-to-Debt is 1.61. VentriPoint Diagnostics' value of 0.13 is 91.9% below this benchmark. Historically, VentriPoint Diagnostics' own Cash-to-Debt has ranged from 0.01 to 10,000.00 over the past decade. While the company's 10-year median is 3.14 vs. the industry median of 1.61, VentriPoint Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.61, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VentriPoint Diagnostics's current Cash-to-Debt of 0.13 is 91.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current Cash-to-Debt is 0.13, which is 96% below median its own 10-year median of 3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Cash-to-Debt of 0.13. The current Cash-to-Debt is 0.13, which is 96% below median its 10-year median of 3.14 and 91.9% below the Medical Devices & Instruments industry median of 1.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Cash-to-Debt is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
